Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
复制标题
DOI：
10.1097/rlu.0000000000002130
复制
发表时间：
2018-07
影响因子：
10.6
通讯作者：
Jadvar H
中科院分区：
文献类型：
--
作者：
Chau A;Gardiner P;Colletti PM;Jadvar H
18F-氟鹿草碱是一种合成氨基酸放射性示踪剂，最近在欧洲和美国获批用于既往明确治疗后前列腺癌生化复发（BCR）男性的正电子发射断层扫描（PET）成像。准确识别前列腺癌BCR患者的疾病部位对于确定适当的治疗非常重要。骨是前列腺癌患者最常见的转移性疾病部位。我们对18 F-氟草苷PET-计算机断层扫描（PET/CT）诊断性能的可用临床前和临床数据进行了全面审查，试图得出关于18 F-氟草苷PET/CT在前列腺癌骨转移性疾病定位中的实用性和局限性的实用和一般性结论。累积的临床前数据和一些回顾性和两项前瞻性临床研究的结果表明，18F-氟鹿草碱可以检测前列腺癌BCR和既往骨特异性成像结果阴性的患者的早期骨髓受累。18F-Fluciclovine PET/CT似乎为前列腺癌BCR男性骨转移的早期检测提供了有用的信息。将需要进行额外的研究，以比较18F-fluciclovine PET/CT与其他标准和新型成像方法在疾病的初始分期、BCR和去势抵抗期的诊断性能。
18F-fluciclovine is a synthetic amino acid radiotracer that has recently been approved in Europe and the United States for positron emission tomography (PET) imaging in men with biochemical recurrence (BCR) of prostate cancer following prior definitive treatment. Accurate identification of the sites of disease in patients presenting with BCR of prostate cancer is important in determining the appropriate treatment. Bone is the most frequent site of metastatic disease in patients with prostate cancer. We conducted a comprehensive review of the available preclinical and clinical data on the diagnostic performance of 18F-fluciclovine PET-computed tomography (PET/CT) in an attempt to draw practical and general conclusions on the utility and limitations of 18F-fluciclovine PET/CT in localization of osseous metastatic disease in prostate cancer. The cumulative preclinical data and results of some retrospective and two prospective clinical studies suggest that 18F-fluciclovine can detect early bone marrow involvement in patients with BCR of prostate cancer and negative prior bone specific imaging findings. 18F-Fluciclovine PET/CT appears to offer useful information for early detection of bone metastases in men with BCR of prostate cancer. Additional investigations will be needed to compare the diagnostic performance of 18F-fluciclovine PET/CT to other standard and novel imaging methods in initial staging, BCR and castrate-resistant phases of disease.